Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
38
Not yet recruiting, industry sponsors, Neurology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting130
- Completed1,020
38 trials
Showing 1 to 25, recently updated first.
BiogenBiogen (BIIB)
NCT07939802 · 75 participants (planned) · Start Nov 19, 2026 · Primary completion Sep 19, 2028
Drug: Felzartamab; Placebo · For: Generalized Myasthenia Gravis
- Clinical Trial of GenSci136 in Patients With Myasthenia GravisNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07936084 · 72 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: GenSci136 for injection · For: Patients With MG (gMG and oMG)
Sites: Shanghai, China
- An Open-label Long-term Safety Study of Buntanetap in Participants With ADPivotal-lookingNot yet recruiting
Annovis Bio Inc.Industry
NCT07757204 · 400 participants (planned) · Start Nov 21, 2026 · Primary completion Feb 21, 2030
Drug: buntanetap/posiphen · For: Alzheimer's Dementia (AD)
Sites: Englewood, Colorado; Daytona Beach, Florida; Maitland, Florida · 14 sites in all
- Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson DiseaseNot yet recruiting
InnoMedica Schweiz AGIndustry
NCT06431971 · 40 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: Talineuren; Placebo · For: Parkinson Disease
Sites: Aarau, Switzerland; Geneva, Switzerland; Sankt Gallen, Switzerland · 6 sites in all
- A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's DiseasePivotal-lookingNot yet recruiting
Vigonvita Life SciencesIndustry
NCT07905352 · 200 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: Simenafil Hydrochloride Tablets 2.5 mg; Simenafil Hydrochloride Tablets 5 mg and 2 more · For: Alzheimer Disease
Sites: Beijing, China
- Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)Not yet recruiting
AskBio IncIndustry
NCT07215403 · 18 participants (planned) · Start Nov 2026 · Primary completion Apr 30, 2028
Drug: AB-1005 · For: PARKINSON DISEASE (Disorder)
Sites: Cleveland, Ohio; Columbus, Ohio; Pittsburgh, Pennsylvania · 4 sites in all
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseaseNot yet recruiting
CRISPR TherapeuticsIndustry
NCT07804004 · 220 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 30, 2029
Drug: CTX112 · For: Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and 2 more
- A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's DiseasePivotal-lookingNot yet recruiting
Mthera Pharma Co., Ltd.Industry
NCT06175767 · 120 participants (planned) · Start Sep 2027 · Primary completion Jan 2028
Drug: MT101-5 · For: Parkinson's Disease
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07503340 · 25 participants (planned) · Start Oct 30, 2026 · Primary completion Aug 31, 2029
Drug: Ocrelizumab co-formulated with rHuPH20 · For: Relapsing-remitting Multiple Sclerosis
AbelZeta Inc.Industry
NCT07825389 · 119 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: C-CAR168 · For: Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS) and 6 more
Sites: Gilbert, Arizona; La Jolla, California
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07857135 · 140 participants (planned) · Start Oct 3, 2026 · Primary completion Feb 3, 2029
Drug: SYS6088; Regorafenib and 1 more · For: Advanced/Metastatic Solid Tumors
Rinri TherapeuticsIndustry
NCT07032038 · 20 participants (planned) · Start Sep 2027 · Primary completion May 2029
Drug: Otic neural progenitors · For: Sensorineural Hearing Loss; Presbyacusis; Auditory Neuropathy
Sites: Birmingham, United Kingdom; Cambridge, United Kingdom; London, United Kingdom
- 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's PatientsNot yet recruiting
MTI Biotech IncIndustry
NCT06432166 · 48 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 30, 2028
Drug: 2-hydroxybenzylamine acetate · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Nashville, Tennessee
- Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase InhibitorPivotal-lookingNot yet recruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07832383 · 135 participants (planned) · Start Oct 2026 · Primary completion May 2028
Drug: NBI-1117567; Placebo · For: Alzheimer's Disease
- A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingNot yet recruiting
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.Industry
NCT07833618 · 150 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 1, 2028
Drug: ALT001 1.0 μg/kg; ALT001 2.0 μg/kg and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Beijing, China
- Efficacy and Safety of Tazbentetol in ALS ParticipantsPivotal-lookingNot yet recruiting
SpinogenixIndustry
NCT07325591 · 430 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: Tazbentetol; placebo · For: Amyotrophic Lateral Sclerosis
- Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's DiseasePivotal-lookingNot yet recruiting
Regeneration Biomedical, Inc.Industry
NCT07205601 · 115 participants (planned) · Start Oct 2026 · Primary completion Feb 2029
Drug: RB-ADSC · For: Alzheimer Disease
- A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)Not yet recruiting
BayerBayer (BAYRY)
NCT07566429 · 8 participants (planned) · Start Jan 25, 2027 · Primary completion Jun 15, 2029
Drug: AB-1005 · For: Parkinson Disease
Sites: Nagoya, Japan; Yokohama, Japan; Toyonaka, Japan · 6 sites in all
Q Therapeutics, Inc.Industry
NCT02478450 · 30 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Q-Cells · For: Amyotrophic Lateral Sclerosis
- A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's DiseasePivotal-lookingNot yet recruiting
Energenesis Biomedical Co., Ltd.Industry
NCT07647614 · 105 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 1, 2030
Drug: 60 milligrams of ENERGI-F705 Tablets; Placebo tablets and 1 more · For: Parkinson's Disease (PD)
Sites: New Taipei City, Taiwan; Taipei, Taiwan
- A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's DiseasePivotal-lookingNot yet recruiting
Merry Life Biomedical Co., Ltd.Industry
NCT07612150 · 210 participants (planned) · Start Aug 1, 2026 · Primary completion Apr 30, 2028
Drug: TML-6 · For: Alzheimer Disease
- [18F]F-AraG PET Imaging in Alzheimer's DiseaseNot yet recruiting
CellSight Technologies, Inc.Industry
NCT07611357 · 10 participants (planned) · Start May 16, 2026 · Primary completion Sep 16, 2029
Drug: Drug: [18F]F-AraG (PET tracer) · For: Alzheimer Disease (AD)
- A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor FluctuationsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07585565 · 276 participants (planned) · Start May 2026 · Primary completion Mar 2028
Drug: GM1; GM1 and 4 more · For: Parkinson's Disease
- A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 MutationsNot yet recruiting
Shanghai Vitalgen BioPharma Co., Ltd.Industry
NCT07414290 · 17 participants (planned) · Start May 25, 2026 · Primary completion Sep 1, 2027
Drug: VGN-R08b 4.2×10^13 vg; VGN-R08b 8.4×10^13 vg and 1 more · For: Parkinson Disease (PD)
Sites: Changsha, China
- A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS PatientsPivotal-lookingNot yet recruiting
PLL TX AUSTRALIA PTY LTDIndustry
NCT06513546 · 153 participants (planned) · Start Apr 8, 2026 · Primary completion Dec 15, 2026
Drug: PLL001 or placebo daily subcutaneous injections · For: Amyotrophic Lateral Sclerosis; ALS
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.